JPRN-UMIN000047035招募中未知
A Phase II Study of Anamorelin and Ipilimumab plus Nivolumab in non-small cell lung cancer (NSCLC) patients with Cancer Cachexia - NEJ058A
PO North East Japan Study Group0 个研究点目标入组 33 人开始时间: 2022年3月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 33
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 79years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Allergy for drugs used in this study (2) Congestive heart failure, myocardial infarction, complete AV block etc, QTc longer than 470msec (3) Contraindication drug for Anamorelin (4) Double cancer (5) Other cancer treatments such as cytotoxic drug, immunotherapy, biological drug, and hormone therapy (6) Apparent interstitial lung disease (ILD) diagnosed by Chest X-ray (7) Active B hepatitis (8) Primary immunodeficiency (9) Gastrointestinal obstruction, post total gastrectomy, active bowel inflammation such asCrohn disease and ulcerative colitis (10) Sever complications (11) Steroid treatment for more than 4 weeks (12) Autoimmune disease (13) Pregnancy and its possibilities (14) Post organ implantation (15) Other inappropriate conditions judged by doctors
研究者
相似试验
进行中（未招募）
不适用
A Phase II Study of the Combination of Ipilimumab and Fotemustine in Patients with Unresectable Locally Advanced or Metastatic Malignant Melanoma - NIBIT-M1EUCTR2010-019356-50-ITIBIT (NETWORK ITALIANO PER LA BIO-IMMUNOTERAPIA DEI TUMORI)
招募中
2 期
A phase II study of ipilimumab, nivolumab, and radiotherapy for advanced NSCLCJPRN-jRCTs021220003Miyauchi Eisaku40
进行中（未招募）
1 期
Study of Nivolumab plus Ipilimumab, Ipilimumab or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate CancerEUCTR2016-001928-54-DKBristol-Myers Squibb International Corporation489
进行中（未招募）
1 期
Study of Nivolumab plus Ipilimumab, Ipilimumab or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate CancerMetastatic Castration-Resistant Prostate CancerMedDRA version: 21.1Level: PTClassification code: 10036909Term: Prostate cancer metastatic Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10076506Term: Castration-resistant prostate cancer Class: 10029104CTIS2022-502909-15-00477
进行中（未招募）
1 期
Study of Nivolumab plus Ipilimumab, Ipilimumab or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate CancerMetastatic Castration-Resistant Prostate CancerMedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001928-54-DEBristol-Myers Squibb International Corporation489